Clinical and economic benefits of human skin allografts in severe burn management: A systematic umbrella review

Human skin allografts (HSAs) have emerged as a promising treatment for severe burns, yet their clinical and economic benefits compared to standard therapies remain incompletely characterized. This systematic review analysed 30 studies (2010-2023) from PubMed/Web of Science, including randomized trials, meta-analyses and observational studies. We evaluated clinical outcomes (healing time, infection rates, mortality) and economic impacts (cost savings, resource utilization) using AMSTAR 2 for quality assessment. HSAs demonstrated superior outcomes versus alternatives: 32-45% lower infection rates (OR 0.62, p